Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Advances and challenges on the in vitro production of secondary metabolites from medicinal plants

Full text
Cardoso, Jean Carlos [1] ; de Oliveira, Maria Eduarda B. S. [1] ; Cardoso, I, Fernanda de C.
Total Authors: 3
[1] I, Univ Fed Sao Carlos UFSCar, Araras, SP - Brazil
Total Affiliations: 1
Document type: Journal article
Source: Horticultura Brasileira; v. 37, n. 2, p. 124-132, APR-JUN 2019.
Web of Science Citations: 1

ABSTRACT The production of secondary metabolites from medicinal plants, also called Plant-Derived Medicinal Compounds (PDMC), is gaining ground in the last decade. Concomitant to the increase in the knowledge about pharmacological properties of these compounds, horticultural plants are becoming the most important, sustainable and low-cost biomass source to obtain high-complex PDMCs to be used as medicaments. Biotechnological tools, including plant cell and tissue culture and plant genetic transformation, are increasingly being employed to produce high quality and rare PDMC under in vitro conditions. The proper use of these technologies requires studies in organogenesis to allow for better control of in vitro plant development and, thus, to the production of specific tissues and activation of biochemical routes that result in the biosynthesis of the target PDMCs. Either biotic or abiotic factors, called elicitors, are responsible for triggering the PDMC synthesis. In vitro techniques, when compared to the conventional cultivation of medicinal plants in greenhouse or in the field, have the advantages of (1) producing PDMCs in sterile and controlled environmental conditions, allowing better control of the developmental processes, such as organogenesis, and (2) producing tissues with high PDMC contents, due to the efficient use of different biotic and abiotic elicitors. Nevertheless, the process has many challenges, e.g., the establishment of step-by-step protocols for in vitro biomass and PDMC production, both involving and being affected by many factors. Other limitations are the high costs in opposition to the relatively cheaper alternative of growing medicinal plants conventionally. This paper aims to quickly review the general origin of plant secondary metabolites, the leading techniques and recent advances for PDMC in vitro production, and the challenges around the use of this promising technology. (AU)

FAPESP's process: 19/00243-7 - In vitro calogenesis as alternative to phyllanthine and hypophyllanthine production in Phyllantus amarus
Grantee:Maria Eduarda Barboza Souza de Oliveira
Support Opportunities: Scholarships in Brazil - Scientific Initiation